ATE305932T1 - Rapanycin29-enole - Google Patents

Rapanycin29-enole

Info

Publication number: ATE305932T1
Authority: AT; Austria
Prior art keywords: enole; enols; useful; treatment; solid tumors
Prior art date: 2001-08-22

Application number

AT02768642T

Other languages

English (en)

Inventor

Tianmin Zhu

Mahdi Bakir Fawzi

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-22

Filing date

2002-08-21

Publication date

2005-10-15

2002-08-21 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305932T1 publication Critical patent/ATE305932T1/de

Links

206010028980 Neoplasm Diseases 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000000508 neurotrophic effect Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)

AT02768642T 2001-08-22 2002-08-21 Rapanycin29-enole ATE305932T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31421101P	2001-08-22	2001-08-22
PCT/US2002/026622 WO2003018573A1 (en)	2001-08-22	2002-08-21	Rapamycin 29-enols

Publications (1)

Publication Number	Publication Date
ATE305932T1 true ATE305932T1 (de)	2005-10-15

Family

ID=23219037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02768642T ATE305932T1 (de)	2001-08-22	2002-08-21	Rapanycin29-enole

Country Status (12)

Country	Link
US (1)	US6677357B2 (de)
EP (1)	EP1419154B1 (de)
JP (1)	JP2005501868A (de)
CN (1)	CN1310908C (de)
AT (1)	ATE305932T1 (de)
BR (1)	BR0211986A (de)
CA (1)	CA2455308A1 (de)
DE (1)	DE60206512T2 (de)
DK (1)	DK1419154T3 (de)
ES (1)	ES2246409T3 (de)
MX (1)	MXPA04001524A (de)
WO (1)	WO2003018573A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1389209B1 (de) *	2001-04-24	2009-04-08	Purdue Research Foundation	Folat-mimetika und deren folatrezeptorbindende konjugate
US20030176455A1 (en) *	2002-03-13	2003-09-18	Wyeth	Method of inhibiting cell death
KR20040106547A (ko) *	2002-05-15	2004-12-17	엔도사이트, 인코포레이티드	비타민-마이토마이신 공액체
RU2344821C2 (ru)	2002-07-30	2009-01-27	Уайт	Парентеральные композиции, содержащие гидроксиэфиры рапамицина
US7601332B2 (en)	2003-01-27	2009-10-13	Endocyte, Inc.	Vitamin receptor binding drug delivery conjugates
WO2004089369A2 (en) *	2003-04-11	2004-10-21	Cambridge University Technical Services Limited	Methods and means for treating protein conformational disorders
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
CN101098854B (zh)	2004-07-23	2012-12-05	恩多塞特公司	二价连接体及其轭合物
US8313763B2 (en)	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
CA2582374A1 (en) *	2004-10-04	2006-04-20	Qlt Usa, Inc.	Ocular delivery of polymeric delivery formulations
US8021849B2 (en)	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
US7632307B2 (en) *	2004-12-16	2009-12-15	Advanced Cardiovascular Systems, Inc.	Abluminal, multilayer coating constructs for drug-delivery stents
EP1828203A2 (de)	2004-12-20	2007-09-05	Wyeth	Rapamycinderivate und ihre verwendung bei der behandlung von nervenerkrankungen
RU2394036C2 (ru)	2004-12-20	2010-07-10	Вайет	Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний
JP2008530090A (ja)	2005-02-09	2008-08-07	ワイス	Ｃｃｉ−７７９多形及びその使用
AU2006221024A1 (en) *	2005-03-07	2006-09-14	Wyeth	Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
JP2008537543A (ja) *	2005-03-07	2008-09-18	ノバルティスアクチエンゲゼルシャフト	神経変性状態に関与する遺伝子
CN101175757B (zh) *	2005-03-16	2012-11-14	恩多塞特公司	蝶酸及其缀合物的合成和纯化
JP2008539276A (ja) *	2005-04-27	2008-11-13	ユニバーシティオブフロリダリサーチファウンデーション，インコーポレイティド	ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
RU2470668C2 (ru) *	2005-08-19	2012-12-27	Эндосайт, Инк.	Конъюгаты лиганда с несколькими лекарственными средствами
JP2009504783A (ja) *	2005-08-19	2009-02-05	エンドサイト，インコーポレイテッド	ビンカアルカロイド、類似体および誘導体のリガンド結合体
JP2009520818A (ja) *	2005-12-20	2009-05-28	ワイス	薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414909B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20100104626A1 (en) *	2007-02-16	2010-04-29	Endocyte, Inc.	Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) *	2007-03-14	2014-11-05	恩多塞特公司	结合配体连接的微管溶素递药缀合物
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
BRPI0812970A2 (pt) *	2007-06-25	2019-09-24	Endocyte Inc	conjugados contendo espaçadores hidrofílicos
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
EP2209374B1 (de)	2007-10-25	2014-12-03	Endocyte, Inc.	Tubulysine und verfahren zu ihrer herstellung
CA2937492C (en)	2008-11-11	2019-08-13	The Board Of Regents Of The University Of Texas System	Inhibition of mammalian target of rapamycin
WO2015161139A1 (en)	2014-04-16	2015-10-22	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US10391059B2 (en)	2009-11-11	2019-08-27	Rapamycin Holdings, Inc.	Oral rapamycin nanoparticle preparations and use
WO2013013708A1 (en)	2011-07-26	2013-01-31	Fundació Institut D'investigació Biomèdica De Bellvitge	Treatment of acute rejection in renal transplant
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
WO2013126797A1 (en)	2012-02-24	2013-08-29	Purdue Research Foundation	Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en)	2012-03-29	2014-03-20	Endocyte, Inc.	Processes for preparing tubulysin derivatives and conjugates thereof
CN103705925B (zh)	2012-09-29	2018-03-30	段磊	抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en)	2012-09-29	2017-09-05	Targeted Therapeutics, Llc	Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US20150290176A1 (en)	2012-10-12	2015-10-15	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
EA201590622A1 (ru)	2012-10-16	2015-10-30	Эндосайт, Инк.	Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
US20160030401A1 (en)	2013-03-13	2016-02-04	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
CN109843301B (zh)	2016-04-14	2022-05-27	斯宾纳克生物科学公司	用于递送治疗剂的含金属硅酸盐的多孔硅材料
EP3848065B1 (de)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN113939324A (zh)	2019-04-08	2022-01-14	巴德外周血管股份有限公司	在经改性装置表面上具有药物洗脱涂层的医疗装置
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
EP0378318A1 (de) *	1989-01-11	1990-07-18	Merck & Co. Inc.	Verfahren zur Herstellung von FK-506 sowie Tricarbonylzwischenprodukten
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB2247456A (en) *	1990-09-03	1992-03-04	Fujisawa Pharmaceutical Co	Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
DE69209183T2 (de)	1991-06-18	1996-08-08	American Home Prod	Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en)	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5621108A (en) *	1994-12-05	1997-04-15	Trustees Of The University Of Pennsylvania	Processes and intermediates for preparing macrocycles
US5563145A (en) *	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
CN1235608A (zh) *	1996-09-09	1999-11-17	美国家用产品公司	烷基化的雷帕霉素衍生物
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US6680330B2 (en)	2001-08-22	2004-01-20	Wyeth	Rapamycin dialdehydes

2002
- 2002-08-21 EP EP02768642A patent/EP1419154B1/de not_active Expired - Lifetime
- 2002-08-21 ES ES02768642T patent/ES2246409T3/es not_active Expired - Lifetime
- 2002-08-21 CN CNB028163052A patent/CN1310908C/zh not_active Expired - Fee Related
- 2002-08-21 AT AT02768642T patent/ATE305932T1/de not_active IP Right Cessation
- 2002-08-21 DE DE60206512T patent/DE60206512T2/de not_active Expired - Fee Related
- 2002-08-21 MX MXPA04001524A patent/MXPA04001524A/es active IP Right Grant
- 2002-08-21 JP JP2003523235A patent/JP2005501868A/ja active Pending
- 2002-08-21 DK DK02768642T patent/DK1419154T3/da active
- 2002-08-21 BR BR0211986-2A patent/BR0211986A/pt not_active IP Right Cessation
- 2002-08-21 CA CA002455308A patent/CA2455308A1/en not_active Withdrawn
- 2002-08-21 WO PCT/US2002/026622 patent/WO2003018573A1/en not_active Ceased
- 2002-08-22 US US10/224,971 patent/US6677357B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2005501868A (ja)	2005-01-20
BR0211986A (pt)	2004-09-28
DK1419154T3 (da)	2006-01-09
EP1419154B1 (de)	2005-10-05
WO2003018573A1 (en)	2003-03-06
US6677357B2 (en)	2004-01-13
CN1545511A (zh)	2004-11-10
US20030114477A1 (en)	2003-06-19
MXPA04001524A (es)	2004-05-31
CN1310908C (zh)	2007-04-18
DE60206512T2 (de)	2006-06-22
CA2455308A1 (en)	2003-03-06
EP1419154A1 (de)	2004-05-19
DE60206512D1 (de)	2006-02-16
ES2246409T3 (es)	2006-02-16

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60206512D1 (de)	2006-02-16	Rapanycin29-enole
MXPA04001523A (es)	2004-05-31	Dialdehidos de rapamicina.
DE50306232D1 (de)	2007-02-15	Ampholytisches copolymer und dessen verwendung
WO2002026746A3 (en)	2002-08-15	1-oxorapamycins
YU9404A (sh)	2006-08-17	Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0113975A (pt)	2003-07-29	ésteres de rapamicina solúveis em água
SG149063A1 (en)	2009-01-29	Use of modified cyclosporins for the treatment of hcv disorders
NO20034056D0 (no)	2003-09-12	Proliferative sykdommer
DE60137337D1 (de)	2009-02-26	Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CO5611160A2 (es)	2006-02-28	Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
WO2002028867A3 (en)	2002-08-29	Ethers of 7-desmethylrapamycin for use in immunosuppression
BRPI0307673A2 (pt)	2016-11-08	métodos de tratar doença vascular.
EP1432714A4 (de)	2005-10-19	Chemische verbindungen
WO2003101401A3 (en)	2004-12-09	Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2002028866A3 (en)	2002-08-15	Hydroxyesters of 7-desmethylrapamycin
WO2001098317A3 (en)	2002-09-26	Alpha-glycosylceramides for treating bacterial and fungal infections
DK1560812T3 (da)	2006-09-04	Aminocyclohexyletherforbindelser og anvendelser deraf
WO2004031129A3 (en)	2004-07-15	Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2004041158A3 (en)	2004-07-15	Rifalazil compositions and therapeutic regimens
WO2005030794A3 (en)	2005-08-18	Hemiasterlin derivatives and uses thereof
WO2003051299A3 (en)	2003-12-24	Sulfhydryl rifamycins and uses thereof
WO2004045545A3 (en)	2004-08-12	Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2007059341A3 (en)	2007-11-29	Pyrazolothiazole protein kinase modulators
NO20053903D0 (no)	2005-08-22	Nukleotidlipidesterderivater.
ATE418613T1 (de)	2009-01-15	Antimikrobielle zusammensetzungen